As part of its collaboration agreement with the French firm, Cellectis is eligible for an undisclosed payment.
Signed in February 2014, the collaboration is focused on research, development and potentially commercialization of five product candidates targeting leukemia and solid tumors.
Cellectis is the gene-editing company that employs proprietary technologies to develop CAR T-cell products in adoptive immunotherapy for cancer.
Servier Oncology Innovation Therapeutic Pole director Jean-Pierre Abastado said: "We believe that immunotherapy will dramatically change the management of metastatic cancers.
"Our goal at Servier is to make these new technologies available for the largest number of cancer patients."
Servier’s development is driven by the pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, central nervous system, psychiatric, rheumatologic diseases, as well as cancer.